LifeArc logo

LifeArc

Europe, England, United Kingdom, London

Description

LifeArc is an independent life science medical research charity committed to drastically improving positive patient outcomes everywhere.

Investor Profile

LifeArc has made 15 investments, with 0 in the past 12 months and 27% as lead.

Stage Focus

  • Seed (40%)
  • Series B (13%)
  • Series A (13%)
  • Series Unknown (13%)
  • Angel (7%)
  • Convertible Note (7%)
  • Grant (7%)

Country Focus

  • United Kingdom (73%)
  • United States (20%)
  • Sweden (7%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Biopharma
  • Medical
  • Machine Learning
  • Life Science
  • Clinical Trials
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does LifeArc frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 2
Pfizer Venture Investments
North America, New York, United States, New York
Co-Investments: 2
Johnson & Johnson Innovation – JJDC
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Advent Life Sciences
Europe, England, United Kingdom, London
Co-Investments: 2
Ananda Impact Ventures
Europe, Bayern, Germany, Munich
Co-Investments: 1
Business Growth Fund
Europe, England, United Kingdom, London
Co-Investments: 1
Dementia Discovery Fund
Europe, England, United Kingdom, London
Co-Investments: 3
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Cambridge Angels group
Europe, England, United Kingdom, London
Co-Investments: 1
Downing Ventures
Europe, England, United Kingdom, London
Co-Investments: 1

What are some of recent deals done by LifeArc?

OxCan

Oxford, Oxfordshire, United Kingdom

OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection.

BiotechnologyHealth CareMachine Learning
SeedJan 10, 2023
Amount Raised: $3,645,900
AviadoBio

London, England, United Kingdom

AviadoBio transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies

BiotechnologyHealth Care
Series ADec 2, 2021
Amount Raised: $77,936,207
Closed Loop Medicine

London, England, United Kingdom

Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians

Health CarePharmaceuticalTherapeutics
SeedNov 3, 2021
Amount Raised: $17,802,318
Eliem Therapeutics

Redmond, Washington, United States

Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.

BiotechnologyHealth CarePharmaceutical
Series BMay 24, 2021
Amount Raised: $60,000,000
Cumulus Neuroscience

Belfast, Belfast, United Kingdom

Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform.

Health Care
Series UnknownMay 4, 2021
Amount Raised: $8,332,523
DJS Antibodies

Headington, Oxfordshire, United Kingdom

DJS Antibodies designs and discovers novel therapeutic monoclonal antibodies against GPCRs.

BiotechnologyHealth CareTherapeutics
SeedDec 22, 2020
Amount Raised: $8,039,468
BrainWaveBank

Belfast, Belfast, United Kingdom

BrainWaveBank makes it possible to measure and track brain activity and cognitive performance for anyone, anytime, anywhere.

Clinical TrialsHealth CareHealth DiagnosticsMedical DevicemHealthNeurosciencePharmaceutical
Convertible NoteDec 8, 2020
Amount Raised: $8,019,000
Vicore Pharma

Mölndal, Vastra Gotaland, Sweden

Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders.

BiopharmaBiotechnologyPharmaceutical
GrantJun 3, 2020
Amount Raised: $1,500,000
PolyProx

Cambridge, Cambridgeshire, United Kingdom

PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment.

BiotechnologyHealth CareOncologyTherapeutics
SeedMar 2, 2020
Amount Raised: $1,276,588
Ikarovec

Cambridge, Cambridgeshire, United Kingdom

Ikarovek is working on early stage assets intended for the treatment of diabetic macular edama.

BiotechnologyHealth CareLife Science
SeedFeb 5, 2020
Amount Raised: $3,249,285